New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 17, 2014
12:25 EDTBLUE, BLUE, BMRN, BMRN, CELG, CELG, CLDN, CLDN, MDGN, MDGN, QURE, QURE, SGMO, SGMO, AGTC, AGTC, ALGN, ALGNPiper Jaffray biopharm analyst holds an analyst/industry conference call
Biopharmaceuticals Analyst Schimmer discusses gene therapy and highlights public and private companies involved in the field, as well as the large-cap pharma partnerships on an Analyst/Industry conference call. Relevant companies AGTC, ALGN, BLUE, BMRN, CELG, CLDN, MDGN, QURE and SGMO may be included on the Analyst/Industry conference call to be held on June 18 at 2 pm.
News For AGTC;ALGN;BLUE;BMRN;CELG;CLDN;MDGN;QURE;SGMO From The Last 14 Days
Check below for free stories on AGTC;ALGN;BLUE;BMRN;CELG;CLDN;MDGN;QURE;SGMO the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 26, 2014
18:20 EDTBMRNOn The Fly: After Hours Movers
UP AFTER EARNINGS: TubeMogul (TUBE), up 31.8% after reporting better than expected second quarter results and guidance above analyst estimates... Aruba Networks (ARUN), up 2.3% after reporting quarterly results and announcing a 3.7% workforce reduction... HEICO (HEI), up 2.3% after raising fiscal 2014 net income guidance. ALSO HIGHER: Chemtura (CHMT) and Diebold (DBD) are both up marginally after Mario Gabelli commented on the companies in an interview with CNBC. DOWN AFTER EARNINGS: Smith & Wesson (SWHC), down 10.2% after reporting disappointing first quarter results and lowering fiscal 2014 outlook. ALSO LOWER: Sturm, Ruger (RGR), down 4% after Smith & Wesson reported quarterly results... BioMarin (BMRN), down 1.35 after lowering fiscal 2014 revenue guidance.
16:36 EDTBMRNBioMarin lowers FY14 revenue view to $680M-$700M from $745M-$765M
Subscribe for More Information
11:20 EDTCELGCelgene added to short term buy list at Deutsche Bank
Subscribe for More Information
09:35 EDTCELGActive equity options trading on open
Subscribe for More Information
August 25, 2014
12:19 EDTCELGOn The Fly: Midday Wrap
Subscribe for More Information
10:40 EDTCELGBiotechs rise after InterMune acquired by Roche
Subscribe for More Information
August 21, 2014
07:00 EDTAGTCApplied Genetic price target raised to $24 from $21 at Cantor
Subscribe for More Information
August 20, 2014
08:02 EDTCELGBristol-Myers, Celgene enter collaboration agreement for OPDIVO, ABRAXANE
Subscribe for More Information
August 19, 2014
09:38 EDTCELGActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL GILD TSLA CELG VLO VZ FB HD
07:33 EDTCELGCelgene announces publication of REVLIMID combination results
Celgene announced that results of a study evaluating the combination of REVLIMID with rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate and prednisone in untreated diffuse large b-cell lymphoma were published online ahead of print in the Journal of Clinical Oncology. In a phase II, open label, single arm study, 64 patients with newly diagnosed, untreated, stage II-IV CD20 positive DLBCL received 25 mg of lenalidomide on days 1-10 with standard dose R-CHOP every 21 days for six cycles. All patients received pegfilgrastim on day two of each cycle and aspirin prophylaxis throughout. The primary endpoint was event-free survival with secondary endpoints of progression free survival and overall survival. A one-stage binomial design was used to assess the efficacy and tolerability of REVLIMID with R-CHOP. Of the 64 patients enrolled, 60 were eligible for response evaluation. In these patients, the overall response rate was 98% with 80% achieving a complete response. The 24-month EFS, which was identical to PFS, and OS rates were 59% and 78%, respectively. The company said, "This study demonstrated that the addition of lenalidomide to conventional R-CHOP resulted in similar PFS rates and OS rates between sub-types. This is intriguing as patients with the non-GCB phenotype have traditionally experienced poorer outcomes. The results of this study support further evaluation of this regimen in this sub-type of DLBCL.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use